Trevena Company Profile (NASDAQ:TRVN)

About Trevena

Trevena logoTrevena Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors (GPCRs). Using its product platform, the Company has identified and advanced three differentiated product candidates: Oliceridine (TRV130), TRV027 and TRV250. Its TRV130 is a Mu-receptor G protein Pathway Selective (Mu-GPS) modulator that activates G protein. Its TRV250 is a small molecule G protein biased ligand of the d-opioid receptor in preclinical development. Its TRV734 is a small molecule Mu-GPS that it has discovered and has developed through Phase I as a first-line, orally administered compound for the treatment of moderate to severe acute and chronic pain. Its TRV027 is a peptide b-arrestin biased ligand that targets the angiotensin II type 1 receptor (AT1R). In addition to these three product candidates, the Company has identified and has completed the Phase I program for TRV734.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: TRVN
  • CUSIP:
Key Metrics:
  • Previous Close: $3.99
  • 50 Day Moving Average: $6.60
  • 200 Day Moving Average: $6.30
  • 52-Week Range: $3.70 - $9.73
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.38
  • P/E Growth: 0.00
  • Market Cap: $208.81M
  • Outstanding Shares: 52,334,000
  • Beta: -0.18
Profitability:
  • Net Margins: -841.00%
  • Return on Equity: -66.50%
  • Return on Assets: -53.74%
Debt:
  • Debt-to-Equity Ratio: 0.15%
  • Current Ratio: 8.02%
  • Quick Ratio: 8.02%
Additional Links:
Companies Related to Trevena:

Analyst Ratings

Consensus Ratings for Trevena (NASDAQ:TRVN) (?)
Ratings Breakdown: 13 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $12.69 (218.10% upside)

Analysts' Ratings History for Trevena (NASDAQ:TRVN)
Show:
DateFirmActionRatingPrice TargetDetails
2/22/2017Roth CapitalSet Price TargetBuy$9.00View Rating Details
2/23/2017Oppenheimer Holdings, Inc.Reiterated RatingOutperform$13.00 -> $10.00View Rating Details
2/23/2017HC WainwrightLower Price TargetBuy -> Buy$11.00 -> $8.00View Rating Details
2/22/2017AegisReiterated RatingBuy -> Positive$14.00View Rating Details
2/22/2017FBR & CoReiterated RatingOutperform -> Outperform$13.00 -> $8.00View Rating Details
2/21/2017Cowen and CompanyReiterated RatingBuyView Rating Details
2/16/2017Jefferies Group LLCReiterated RatingBuy$11.00View Rating Details
2/2/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$15.00View Rating Details
12/16/2016Needham & Company LLCReiterated RatingBuy$11.00View Rating Details
12/1/2016WedbushReiterated RatingOutperform$16.00View Rating Details
10/25/2016Brean CapitalSet Price TargetBuy$14.00View Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$21.00 -> $18.00View Rating Details
3/2/2016WallachBeth CapitalInitiated CoverageBuy$18.00View Rating Details
2/24/2016Barclays PLCLower Price TargetOverweight$18.00 -> $15.00View Rating Details
(Data available from 2/26/2015 forward)

Earnings

Earnings History for Trevena (NASDAQ:TRVN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/7/2017        
11/3/2016Q3 2016($0.40)($0.57)ViewN/AView Earnings Details
5/5/2016Q1($0.32)($0.35)ViewN/AView Earnings Details
3/9/2016Q415($0.26)($0.30)$1.64 million$1.88 millionViewListenView Earnings Details
11/10/2015Q3($0.34)($0.24)ViewN/AView Earnings Details
8/11/2015Q215($0.37)($0.28)$1.88 millionViewN/AView Earnings Details
5/7/2015($0.33)($0.33)ViewN/AView Earnings Details
3/18/2015Q414($0.39)($0.45)ViewN/AView Earnings Details
11/11/2014Q314($0.45)($0.59)ViewN/AView Earnings Details
8/12/2014($0.35)($0.44)ViewN/AView Earnings Details
5/9/2014Q114($0.36)($0.59)$0.03 million$0.04 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Trevena (NASDAQ:TRVN)
Current Year EPS Consensus Estimate: $-1.90 EPS
Next Year EPS Consensus Estimate: $-1.68 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20165($0.33)($0.24)($0.29)
Q2 20165($0.38)($0.27)($0.33)
Q3 20164($0.43)($0.24)($0.35)
Q4 20165($0.60)($0.36)($0.53)
Q1 20173($0.56)($0.46)($0.50)
Q2 20173($0.54)($0.31)($0.41)
Q3 20173($0.50)($0.21)($0.33)
Q4 20173($0.54)($0.17)($0.32)
Q1 20181($0.16)($0.16)($0.16)
Q2 20181($0.16)($0.16)($0.16)
Q3 20181($0.16)($0.16)($0.16)
Q4 20181($0.16)($0.16)($0.16)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Trevena (NASDAQ:TRVN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Trevena (NASDAQ:TRVN)
Insider Ownership Percentage: 3.40%
Institutional Ownership Percentage: 69.28%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/9/2016Carrie L BourdowSVPBuy4,000$4.34$17,360.00View SEC Filing  
11/7/2016Maxine GowenCEOBuy12,500$4.10$51,250.00View SEC Filing  
11/7/2016Yacoub HabibSVPBuy5,000$4.12$20,600.00View SEC Filing  
5/27/2016Maxine GowenCEOBuy22,084$7.12$157,238.08View SEC Filing  
12/10/2015David SoergelCMOSell27,217$10.55$287,139.35View SEC Filing  
12/12/2014John M LimongelliVPBuy3,000$4.14$12,420.00View SEC Filing  
12/10/2014Enterprise Associates 12 NewMajor ShareholderBuy1,000,000$4.00$4,000,000.00View SEC Filing  
12/10/2014Maxine GowenCEOBuy8,000$4.00$32,000.00View SEC Filing  
12/10/2014Michael R DoughertyDirectorBuy7,000$4.00$28,000.00View SEC Filing  
12/10/2014Michael W LarkVPBuy5,000$4.00$20,000.00View SEC Filing  
12/10/2014Roberto CucaCFOBuy25,000$4.00$100,000.00View SEC Filing  
12/9/2014Leon O Moulder JrDirectorBuy30,200$3.96$119,592.00View SEC Filing  
9/29/2014Rosamond DeeganSVPSell44$7.00$308.00View SEC Filing  
2/5/2014Laboratories Holdings L ForestMajor ShareholderBuy428,571$7.00$2,999,997.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Trevena (NASDAQ:TRVN)
DateHeadline
News IconForward Earnings Estimate of Trevena, Inc.(TRVN) - Highland Mirror (NASDAQ:TRVN)
www.highlandmirror.com - February 25 at 3:52 AM
News IconTrevena, Inc. (TRVN) Given a $9.00 Price Target at Roth Capital (NASDAQ:TRVN)
cloudhostinghq.net - February 24 at 10:43 AM
News IconTrevena Inc TRVN Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:TRVN)
www.bioportfolio.com - February 24 at 10:43 AM
News IconTrevena, Inc. (NASDAQ:TRVN) (NASDAQ:TRVN)
eleganthomesinla.com - February 24 at 10:43 AM
thestreet.com logoFirst Week of April 21st Options Trading For Trevena - TheStreet.com (NASDAQ:TRVN)
www.thestreet.com - February 23 at 2:21 AM
News IconAre Analysts Optimistic About Where Trevena, Inc. (NASDAQ:TRVN) is Heading? - Winfield Review (NASDAQ:TRVN)
winfieldreview.com - February 23 at 2:21 AM
News IconThe Technical Charts For Trevena, Inc. (TRVN) Say It All Today - NY Stock News (NASDAQ:TRVN)
nystocknews.com - February 23 at 2:21 AM
News IconFirst Week of April 21st Options Trading For Trevena (NASDAQ:TRVN)
www.stockoptionschannel.com - February 22 at 9:17 PM
smarteranalyst.com logoWe Would Be Buyers of Trevena Inc (TRVN) on Share Weakness, Says Aegis (NASDAQ:TRVN)
www.smarteranalyst.com - February 22 at 9:17 PM
4-traders.com logoTrevena : Announces Positive Top-line Results from Two Phase 3 Pivotal Efficacy Studies of Intravenous Oliceridine in Moderate-to-Severe Acute Pain (NASDAQ:TRVN)
www.4-traders.com - February 22 at 10:27 AM
investorplace.com logoFCX, TRVN and UL stock used more than their fair share of red ink on Tuesday (NASDAQ:TRVN)
investorplace.com - February 22 at 10:27 AM
News IconTrevena Inc (NASDAQ:TRVN) Releases Positive Report From Phase III Pivotal Efficacy Trials Of Intravenous Oliceridine (NASDAQ:TRVN)
wallstreetpr.com - February 22 at 10:27 AM
smarteranalyst.com logoTrevena Inc (TRVN): Olinvo Remains Commercially Viable (NASDAQ:TRVN)
www.smarteranalyst.com - February 22 at 10:27 AM
benzinga.com logoTrevena's 30% Plunge, Explained (NASDAQ:TRVN)
www.benzinga.com - February 21 at 4:38 PM
bizjournals.com logoTrevena's stock drops 30% despite positive study results for pain drug (NASDAQ:TRVN)
www.bizjournals.com - February 21 at 4:38 PM
streetinsider.com logoTrevena (TRVN) Says Two Phase 3 Studies of Oliceridine Achieved Primary Endpoint (NASDAQ:TRVN)
www.streetinsider.com - February 21 at 4:38 PM
schaeffersresearch.com logoLumber Liquidators, Eyegate Pharmaceuticals, Trevena News Today (NASDAQ:TRVN)
www.schaeffersresearch.com - February 21 at 4:38 PM
investopedia.com logoTrevena Plunges 34% On Painkiller Results (TRVN) (NASDAQ:TRVN)
www.investopedia.com - February 21 at 4:38 PM
biz.yahoo.com logoTREVENA INC Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (NASDAQ:TRVN)
us.rd.yahoo.com - February 21 at 4:38 PM
us.rd.yahoo.com logoTrevena's painkiller succeeds in two late-stage studies (NASDAQ:TRVN)
us.rd.yahoo.com - February 21 at 4:38 PM
thestreet.com logoTrevena Makes Case for Better Post-Surgical Opioid with New Study Data (NASDAQ:TRVN)
us.rd.yahoo.com - February 21 at 4:38 PM
thestreet.com logoSarepta Leads Biotech Movers on Voucher Deal News (NASDAQ:TRVN)
us.rd.yahoo.com - February 21 at 4:38 PM
investopedia.com logoTrevena Painkiller Underperforms Morphine (NASDAQ:TRVN)
www.investopedia.com - February 21 at 4:38 PM
News IconTarget Price Review on Trevena, Inc. (NASDAQ:TRVN) - Rockville Register (NASDAQ:TRVN)
rockvilleregister.com - February 19 at 7:14 PM
News IconAnalyst Target Update & Review on Trevena, Inc. (NASDAQ:TRVN ... - Rockville Register (NASDAQ:TRVN)
rockvilleregister.com - February 19 at 8:29 AM
News IconKeeping Tabs on the Technicals For Trevena, Inc. (NASDAQ:TRVN) - BVN (NASDAQ:TRVN)
bvnewsjournal.com - February 17 at 6:58 PM
News IconInsider Activity: Is Management Buying Trevena, Inc. (NASDAQ:TRVN)? - Winfield Review (NASDAQ:TRVN)
winfieldreview.com - February 14 at 6:40 AM
News IconInvestor Technical Review for Trevena Inc. (TRVN) - Baldwin Journal (NASDAQ:TRVN)
baldwinjournal.com - February 14 at 6:40 AM
News IconAre Insiders Bumping Up Their Positions in Trevena, Inc. (NASDAQ:TRVN) - Wall Street Beacon (NASDAQ:TRVN)
wsbeacon.com - January 31 at 5:48 AM
marketnewsvideo.com logoNotable Wednesday Option Activity: STI, TRVN, CCL (NASDAQ:TRVN)
www.marketnewsvideo.com - January 26 at 6:27 AM
News IconTrevena Inc TRVN Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:TRVN)
www.bioportfolio.com - January 22 at 8:01 PM
capitalcube.com logoETFs with exposure to Trevena, Inc. : January 20, 2017 (NASDAQ:TRVN)
www.capitalcube.com - January 21 at 4:14 AM
News IconTrevena, Inc. (NASDAQ: TRVN) Completes Phase 3 Apollo Trials for Oliceridine, Says Athena Study on Track (NASDAQ:TRVN)
missionir.com - January 12 at 5:49 AM
finance.yahoo.com logoTrevena, Inc. (NAS:TRVN) Completes Phase 3 Apollo Trials for Oliceridine, Says Athena Study on Track (NASDAQ:TRVN)
au.finance.yahoo.com - January 12 at 5:49 AM
News IconThousands brave cold for tickets to Obama farewell speech (NASDAQ:TRVN)
flapship.com - January 10 at 2:53 AM
marketexclusive.com logoAnalyst Activity – HC Wainwright Initiates Coverage On Trevena (NASDAQ:TRVN) With a Buy (NASDAQ:TRVN)
marketexclusive.com - January 10 at 2:53 AM
us.rd.yahoo.com logoCoverage initiated on Trevana by H.C. Wainwright (NASDAQ:TRVN)
us.rd.yahoo.com - January 10 at 2:53 AM
marketexclusive.com logoAnalyst Activity – Oppenheimer Holdings, Inc. Initiates Coverage On Trevena (NASDAQ:TRVN) With a Outperform (NASDAQ:TRVN)
marketexclusive.com - January 6 at 6:16 AM
finance.yahoo.com logoCoverage initiated on Trevana by Oppenheimer (NASDAQ:TRVN)
finance.yahoo.com - January 6 at 6:16 AM
streetinsider.com logoTrevena (TRVN) Completes Enrollment of Phase 3 APOLLO Trials of Oliceridine for Moderate-to-Severe Acute Pain (NASDAQ:TRVN)
www.streetinsider.com - January 5 at 7:15 AM
us.rd.yahoo.com logo7:06 am Trevana completes enrollment of Phase 3 APOLLO pivotal efficacy trials of Oliceridine for moderate-to-severe acute pain: data expected in Q1 (NASDAQ:TRVN)
us.rd.yahoo.com - January 5 at 7:15 AM
finance.yahoo.com logoTrevena Completes Enrollment of Phase 3 APOLLO Pivotal Efficacy Trials of Oliceridine for Moderate-to-Severe Acute Pain (NASDAQ:TRVN)
finance.yahoo.com - January 4 at 7:14 AM
biz.yahoo.com logoTREVENA INC Files SEC form 8-K, Regulation FD Disclosure (NASDAQ:TRVN)
biz.yahoo.com - January 4 at 7:14 AM
investornewswire.com logoSentiments And Ratings Alert: Trevena, Inc. (NASDAQ:TRVN) - Investor Newswire (NASDAQ:TRVN)
www.investornewswire.com - December 23 at 2:26 AM
News IconFirst Week of TRVN February 2017 Options Trading (NASDAQ:TRVN)
www.stockoptionschannel.com - December 20 at 4:50 PM
biz.yahoo.com logoTREVENA INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits (NASDAQ:TRVN)
biz.yahoo.com - December 20 at 4:50 PM
marketexclusive.com logoAnalyst Activity – Needham & Company LLC Reiterates Buy on Trevena (NASDAQ:TRVN) (NASDAQ:TRVN)
marketexclusive.com - December 18 at 3:20 AM
News IconChecking in on Signals for Trevena Inc. (TRVN) - Yankee Analysts (NASDAQ:TRVN)
yankeeanalysts.com - December 17 at 4:57 AM
seekingalpha.com logoTrevena - Oliceridine's Limited Market Creates Huge Downside - Seeking Alpha (NASDAQ:TRVN)
seekingalpha.com - December 16 at 6:04 AM
biz.yahoo.com logoTREVENA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation (NASDAQ:TRVN)
biz.yahoo.com - December 15 at 6:49 AM

Social

What is Trevena's stock symbol?

Trevena trades on the NASDAQ under the ticker symbol "TRVN."

Where is Trevena's stock going? Where will Trevena's stock price be in 2017?

13 brokers have issued 12-month price targets for Trevena's shares. Their predictions range from $8.00 to $18.00. On average, they expect Trevena's share price to reach $12.69 in the next year.

When will Trevena announce their earnings?

Trevena is scheduled to release their next quarterly earnings announcement on Tuesday, March, 7th 2017.

What are analysts saying about Trevena stock?

Here are some recent quotes from research analysts about Trevena stock:

  • According to Zacks Investment Research, "Trevena, Inc. is a biopharmaceutical company. It focuses on discovering and developing therapeutics for G protein coupled receptors. The Company's product pipeline includes TRV027, TRV130, TRV734 and Delta opioid biased ligand which are in different clinical phases. Trevena, Inc. is based in King of Prussia, Pennsylvania. " (2/25/2017)

  • HC Wainwright analysts commented, "Following the Phase 3 pivotal APOLLO readouts, and the subsequent ~45% drop in TRVN shares (vs. -1.5% NBI) over the last two trading sessions, we assess the implications of the mixed data set, and suggest likely/ probable clinical settings for use that best match OLINVO's (new brand name for oliceridine) overall therapeutic profile' we believe some physicians may find OLINVO useful at reducing antiemetic use, especially in hard tissue pain (most commonly, knee and hip surgery). Yet despite a more nuanced view than some, we nonetheless acknowledge that APOLLO results are far from the "clean win" we were hoping for." (2/23/2017)
  • Aegis analysts commented, "After presenting results yesterday, Trevena finished the trading day down approximately 40%. We believe there are several contributing factors: (1) the lowest dose 0.1 mg did not prove non-inferiority to that of morphine; (2) on the safety side, improvements on the respiratory and nausea/vomiting measurement did not show statistical significance to that of Morphine; (3) investors may think that the current data set points to an Oliceridine that has no commercial value proposition relative to that of morphine. This could lead to slow market adoption; (4) the company may need a capital raise before the NDA is accepted. If a capital raise is completed with current share price, this may lead to excessive dilution; (5) the Athena open label study may be a little behind schedule which puts further pressure on cash runway of the company. We will be buyers on weakness. We view the situation quite differently. The most important thing in our eye's is that Trevena is likely to have enough data for an NDA in 4Q17 after the Athena trial is completed." (2/22/2017)
  • Cowen and Company analysts commented, "TRVN reported top-line results from the pivotal Ph3 APOLLO trials of oliceridine in." (2/21/2017)

Who owns Trevena stock?

Trevena's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (12.87%), Vivo Capital LLC (3.30%), State Street Corp (1.35%), Putnam Investments LLC (0.82%), Harbourvest Partners LLC (0.60%) and Numeric Investors LLC (0.21%). Company insiders that own Trevena stock include Carrie L Bourdow, David Soergel, Maxine Gowen and Yacoub Habib.

Who sold Trevena stock? Who is selling Trevena stock?

Trevena's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Putnam Investments LLC, AQR Capital Management LLC, Metropolitan Life Insurance Co. NY and Guggenheim Capital LLC.

Who bought Trevena stock? Who is buying Trevena stock?

Trevena's stock was purchased by a variety of institutional investors in the last quarter, including Numeric Investors LLC, Russell Investments Group Ltd., State Street Corp, Ellington Management Group LLC and National Planning Corp. Company insiders that have bought Trevena stock in the last two years include Carrie L Bourdow, Maxine Gowen and Yacoub Habib.

How do I buy Trevena stock?

Shares of Trevena can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Trevena stock cost?

One share of Trevena stock can currently be purchased for approximately $3.99.

Trevena (NASDAQ:TRVN) Chart for Sunday, February, 26, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Trevena (NASDAQ:TRVN)

Earnings History Chart

Earnings by Quarter for Trevena (NASDAQ:TRVN)

Dividend History Chart

Dividend Payments by Quarter for Trevena (NASDAQ:TRVN)

Last Updated on 2/26/2017 by MarketBeat.com Staff